292 related articles for article (PubMed ID: 24021375)
21. [Radiosensitization induced by vemurafenib].
Ducassou A; David I; Delannes M; Chevreau C; Sibaud V
Cancer Radiother; 2013; 17(4):304-7. PubMed ID: 23810304
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.
Yin VT; Wiraszka TA; Tetzlaff M; Curry JL; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2015; 31(4):e112-5. PubMed ID: 24833447
[TBL] [Abstract][Full Text] [Related]
23. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
24. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
25. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
26. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
Patrawala S; Puzanov I
Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
[TBL] [Abstract][Full Text] [Related]
27. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
28. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
29. Vemurafenib-induced progression of breast cancer: a case report and review of the literature.
Novik AV; Protsenko SA; Baldueva IA; Ivantsov AO; Nekhaeva TL; Akhaeva ZY; Yanus GA; Iyevleva AG; Imyanitov EN
Target Oncol; 2016 Apr; 11(2):235-8. PubMed ID: 26264150
[TBL] [Abstract][Full Text] [Related]
30. Vemurafenib and radiosensitization.
Boussemart L; Boivin C; Claveau J; Tao YG; Tomasic G; Routier E; Mateus C; Deutsch E; Robert C
JAMA Dermatol; 2013 Jul; 149(7):855-7. PubMed ID: 23699661
[TBL] [Abstract][Full Text] [Related]
31. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma.
Ramani NS; Curry JL; Kapil J; Rapini RP; Tetzlaff MT; Prieto VG; Torres-Cabala CA
Am J Dermatopathol; 2015 Aug; 37(8):e96-9. PubMed ID: 25839886
[TBL] [Abstract][Full Text] [Related]
32. A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it?
Babacan T; Türkbeyler IH; Balakan O; Pehlivan Y; Suner A; Kısacık B
Int J Rheum Dis; 2017 Mar; 20(3):398-401. PubMed ID: 24815010
[TBL] [Abstract][Full Text] [Related]
33. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Sosman JA; Kim KB; Schuchter L; Gonzalez R; Pavlick AC; Weber JS; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Hersey P; Kefford R; Lawrence D; Puzanov I; Lewis KD; Amaravadi RK; Chmielowski B; Lawrence HJ; Shyr Y; Ye F; Li J; Nolop KB; Lee RJ; Joe AK; Ribas A
N Engl J Med; 2012 Feb; 366(8):707-14. PubMed ID: 22356324
[TBL] [Abstract][Full Text] [Related]
34. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
35. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
Fennira F; Pagès C; Schneider P; Sidina I; Viguier M; Basset-Seguin N; Madjlessi-Ezra N; Madelaine I; Bagot M; Battistella M; Porcher R; Mourah S; Lebbé C
Melanoma Res; 2014 Feb; 24(1):75-82. PubMed ID: 24241686
[TBL] [Abstract][Full Text] [Related]
36. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.
Conen K; Mosna-Firlejczyk K; Rochlitz C; Wicki A; Itin P; Arnold AW; Gross M; Zimmermann F; Zippelius A
Dermatology; 2015; 230(1):1-4. PubMed ID: 25472806
[TBL] [Abstract][Full Text] [Related]
37. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib.
Sinha R; Edmonds K; Newton-Bishop J; Gore M; Larkin J; Fearfield L
J Clin Oncol; 2013 Jul; 31(19):e320-1. PubMed ID: 23715570
[No Abstract] [Full Text] [Related]
38. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature.
Ferreira J; Toda-Brito H; Moura MC; Sachse MF; Costa-Rosa J
J Cutan Pathol; 2017 Mar; 44(3):307-309. PubMed ID: 27976808
[No Abstract] [Full Text] [Related]
39. Vemurafenib for the treatment of melanoma.
Jordan EJ; Kelly CM
Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
[TBL] [Abstract][Full Text] [Related]
40. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
Chu EY; Wanat KA; Miller CJ; Amaravadi RK; Fecher LA; Brose MS; McGettigan S; Giles LR; Schuchter LM; Seykora JT; Rosenbach M
J Am Acad Dermatol; 2012 Dec; 67(6):1265-72. PubMed ID: 22609219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]